ZA201504579B - Treatment of circadian rhythm disorders - Google Patents

Treatment of circadian rhythm disorders

Info

Publication number
ZA201504579B
ZA201504579B ZA2015/04579A ZA201504579A ZA201504579B ZA 201504579 B ZA201504579 B ZA 201504579B ZA 2015/04579 A ZA2015/04579 A ZA 2015/04579A ZA 201504579 A ZA201504579 A ZA 201504579A ZA 201504579 B ZA201504579 B ZA 201504579B
Authority
ZA
South Africa
Prior art keywords
treatment
circadian rhythm
rhythm disorders
disorders
circadian
Prior art date
Application number
ZA2015/04579A
Other languages
English (en)
Inventor
Marlene Michelle Dressman
John Joseph Feeney
Louis William Licamele
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201504579(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/751,011 external-priority patent/US8785492B2/en
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of ZA201504579B publication Critical patent/ZA201504579B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2864—Sleep disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA2015/04579A 2012-12-18 2015-06-24 Treatment of circadian rhythm disorders ZA201504579B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261738987P 2012-12-18 2012-12-18
US201261738985P 2012-12-18 2012-12-18
US201361755896P 2013-01-23 2013-01-23
US13/751,011 US8785492B2 (en) 2012-01-26 2013-01-25 Treatment of circadian rhythm disorders
PCT/US2013/023315 WO2013112951A2 (en) 2012-01-26 2013-01-25 Treatment of circadian rhythm disorders
US201361903354P 2013-11-12 2013-11-12
PCT/US2013/076311 WO2014100292A1 (en) 2012-12-18 2013-12-18 Treatment of circadian rhythm disorders

Publications (1)

Publication Number Publication Date
ZA201504579B true ZA201504579B (en) 2023-05-31

Family

ID=50979184

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/04579A ZA201504579B (en) 2012-12-18 2015-06-24 Treatment of circadian rhythm disorders

Country Status (15)

Country Link
US (2) US9730910B2 (ru)
EP (2) EP3767297A1 (ru)
JP (4) JP6144358B2 (ru)
KR (4) KR20150093236A (ru)
CN (2) CN110200958A (ru)
AU (5) AU2013361459A1 (ru)
BR (1) BR112015014619A2 (ru)
CA (2) CA2893542C (ru)
CL (1) CL2015001700A1 (ru)
ES (1) ES2805376T3 (ru)
IL (2) IL266159B2 (ru)
MX (3) MX2015007909A (ru)
RU (1) RU2748386C2 (ru)
WO (1) WO2014100292A1 (ru)
ZA (1) ZA201504579B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014009078A (es) 2012-01-26 2016-01-25 Vanda Pharmaceuticals Inc Tratamiento de trastornos del ritmo circadiano.
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20150093236A (ko) * 2012-12-18 2015-08-17 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
WO2015117048A1 (en) * 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
SI3368534T1 (sl) 2015-10-30 2021-04-30 Neurocrine Biosciences, Inc. Valbenazin ditosilat in njegovi polimorfi
SI3394057T1 (sl) 2015-12-23 2022-06-30 Neurocrine Biosciences, Inc. Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
EA201991784A1 (ru) 2017-01-27 2021-09-23 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
WO2019028245A1 (en) 2017-08-02 2019-02-07 Vanda Pharmaceuticals Inc. USE OF TASIMELTÉON FOR THE TREATMENT OF AFFECTIVE DISORDERS
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
AU2019322863A1 (en) 2018-08-15 2021-03-11 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP3671757A1 (en) * 2018-12-18 2020-06-24 Koninklijke Philips N.V. System and method for determining a level of alertness
KR20240058981A (ko) * 2019-02-13 2024-05-07 반다 파마슈티칼즈, 인코퍼레이티드. 수면 개선 방법
JP6722911B1 (ja) * 2019-04-18 2020-07-15 株式会社こどもみらい 個人別の概日リズムに基づく生活時刻の提示システム
JP7348613B2 (ja) * 2019-04-18 2023-09-21 株式会社こどもみらい 個人別の概日リズムに基づく生活時刻の提示システム
KR20220027977A (ko) * 2019-06-29 2022-03-08 반다 파마슈티칼즈, 인코퍼레이티드. 수면 이상 치료에서의 타시멜테온 용도
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
EP0126630B1 (en) 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
JP4516159B2 (ja) 1995-02-01 2010-08-04 ニューリム ファーマシューティカルズ（１９９１）リミテッド 薬物嗜癖患者の治療のためのメラトニンの使用
JPH11515014A (ja) * 1995-10-24 1999-12-21 グルーエネンタール ゲゼルシャフト ミット ベシュレンクテル ハフツング 哺乳類の概日リズムの調整方法
BR9713690B1 (pt) 1996-12-10 2009-08-11 agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano.
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
AUPO588297A0 (en) 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production
CN1206996C (zh) 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
US6562858B2 (en) 1999-05-17 2003-05-13 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating depression
DK1189900T3 (da) 1999-06-30 2004-04-26 Bristol Myers Squibb Co Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
ES2358416T3 (es) 2001-10-30 2011-05-10 Novartis Ag Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP2005080603A (ja) 2003-09-10 2005-03-31 Kumamoto Technology & Industry Foundation 生体リズム障害の度合の判断方法
WO2005063240A1 (en) 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
EP1696959A2 (en) 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
JP5017268B2 (ja) 2005-07-29 2012-09-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 覚醒を改善する方法
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
CA2950087A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Use of the melatonin agonist (1r-trans)-n[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide in the treatment of circadian and sleep disorders
KR20090024140A (ko) 2006-05-22 2009-03-06 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
JP5590676B2 (ja) 2007-09-13 2014-09-17 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｐｅｒ３ｖｎｔｒ遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測
WO2009084023A2 (en) 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
JP5558016B2 (ja) * 2009-03-17 2014-07-23 株式会社 資生堂 概日リズム調整剤
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
MX2014009078A (es) * 2012-01-26 2016-01-25 Vanda Pharmaceuticals Inc Tratamiento de trastornos del ritmo circadiano.
KR20150093236A (ko) * 2012-12-18 2015-08-17 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료

Also Published As

Publication number Publication date
JP2016506410A (ja) 2016-03-03
KR20150093236A (ko) 2015-08-17
CA3158157A1 (en) 2014-06-26
IL266159B2 (en) 2024-07-01
JP6317503B2 (ja) 2018-04-25
AU2018208633A1 (en) 2018-08-09
NZ709065A (en) 2020-12-18
NZ749282A (en) 2020-12-18
AU2022228094A1 (en) 2022-09-29
CA2893542A1 (en) 2014-06-26
IL266159A (en) 2019-06-30
CN110200958A (zh) 2019-09-06
AU2021203925A1 (en) 2021-07-08
AU2021203925B2 (en) 2022-06-30
EP3767297A1 (en) 2021-01-20
IL239246B (en) 2019-05-30
MX2019006218A (es) 2019-09-06
MX2020012689A (es) 2021-02-15
US20150025086A1 (en) 2015-01-22
EP2934509A1 (en) 2015-10-28
CA2893542C (en) 2022-07-19
RU2015129349A (ru) 2017-01-26
AU2019219847A1 (en) 2019-09-12
KR102269761B1 (ko) 2021-06-28
KR20170058464A (ko) 2017-05-26
EP2934509B1 (en) 2020-05-27
CN105142630A (zh) 2015-12-09
BR112015014619A2 (pt) 2017-07-11
KR20190100429A (ko) 2019-08-28
WO2014100292A1 (en) 2014-06-26
CL2015001700A1 (es) 2015-12-28
JP2017165742A (ja) 2017-09-21
IL239246A0 (en) 2015-07-30
KR20200102545A (ko) 2020-08-31
JP2020090512A (ja) 2020-06-11
MX2015007909A (es) 2016-04-25
ES2805376T3 (es) 2021-02-11
JP2018138554A (ja) 2018-09-06
US9730910B2 (en) 2017-08-15
IL266159B1 (en) 2024-03-01
AU2013361459A1 (en) 2015-07-02
RU2748386C2 (ru) 2021-05-25
JP6144358B2 (ja) 2017-06-07
US20170304256A1 (en) 2017-10-26
KR102148990B1 (ko) 2020-08-27
JP6826216B2 (ja) 2021-02-03

Similar Documents

Publication Publication Date Title
IL266159A (en) Treatment of circadian rhythm disorders
IL233715A0 (en) Treatment of diseases related to the circadian rhythm
HRP20180939T1 (hr) Kombinirana terapija za liječenje multiple skleroze
IL263661A (en) Combination therapy for the treatment of glioblastoma
EP2906208A4 (en) THERAPEUTIC TREATMENT
IL261659A (en) Brain cancer treatment
ZA201205829B (en) Treatment of respiratory disorders
GB201506561D0 (en) Treatment of amblyopia
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
HK1204573A1 (en) Treatment of inflammatory skin disorders
IL225896A0 (en) Treatment of mecp-2 related disorders
LT2802319T (lt) Fiksuotos dozės derinio terapija, skirta parkinsono ligai gydyti
PT2846806T (pt) Tratamento para depressão respiratória
GB201204645D0 (en) Treatment of disease
GB201208505D0 (en) Treatment of skin condition
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201219092D0 (en) Treatment of cardiovascular disease
GB201001912D0 (en) Treatment of respiratory disorders